Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Status:
Completed
Trial end date:
2019-09-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
of TAK-041:
1. Following oral single and multiple doses in healthy participants.
2. As add-on therapy to antipsychotics in stable schizophrenia participants.
3. To determine the oral bioavailability of the TAK-041 tablet formulation compared to the
oral suspension formulation in the fasted state.
4. To assess the effect of food on the PK of TAK-041 in healthy participants.